Showing results for "Opiant Pharmaceuticals Inc."
industries
Zepbound, Ozempic for Weight Loss: Safety, Effectiveness and Shortages, ExplainedObesity is among the world’s most common health conditions, but for years medicine had few effective approaches to offer short of surgery. That’s why there’s been so much excitement about a new class of drugs that’s helping patients shed dozens of pounds at far lower risk — and generating billions in revenue for pharmaceutical companies.May 24, 2024
markets
Nvidia Stock Split Looks to Be First of Many in Tech, BofA SaysNvidia Corp. delighted investors when it announced a 10-for-1 stock split earlier this week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.May 24, 2024
business
RBC’s Top Health-Care Investment Banker Returns to Deutsche BankRoyal Bank of Canada’s global head of health-care investment banking, Andrew “Cal” Callaway, is leaving the firm to return to Deutsche Bank AG where he previously worked for more than a decade, according to people with knowledge of the matter.May 23, 2024
business
Astorg Said to Explore Sale of €4 Billion Ingredient Firm SolinaPrivate equity firm Astorg is exploring options including a potential sale for French food-ingredients maker Solina that could value the business at as much as €4 billion ($4.3 billion), according to people familiar with the matter.May 23, 2024
markets
S&P 500 Companies Adjust GAAP Net Income for More Items, Boost EPSLarge US companies are bolstering their adjusted earnings per share by excluding items such as litigation expenses and amortization of intangible assets from their net income, even as regulators scrutinize such practices, a new analysis finds.May 22, 2024
industries
Weight-Loss Upstart Viking (VKTX) Needs Deal to Vie With Lilly, Novo (LLY, NVO)Hope for a weight-loss drug that’s better than Ozempic and Wegovy has sent Viking Therapeutics Inc. shares skyrocketing. But to reach the next level the biopharmaceutical developer likely needs a partner — or a buyer.May 22, 2024